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Background. Coronary artery disease is the most common cause of death in the patients with nonalcoholic fatty liver disease
(NAFLD). Studies have shown that there is a strong relation between the increase in the aminotransferase levels and fat
accumulation in the liver with cardiovascular complications, independent of all aspects of the metabolic syndrome. This study
aimed to examine the effect of virgin olive oil on alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and the
severity of steatosis in the NAFLD patients undergoing a weight-loss diet.Methods. This clinical trial was carried out on 50 patients
with nonalcoholic fatty liver (mean age of 45.91 ± 9.61 years, mean BMI of 29.7 ± 0.58 Kg/m2) and the subjects were randomly
assigned to the olive oil group (receiving the equivalent of 20% of their total daily energy requirement from olive oil) or the control
group (with normal consumption of oil) for 12 weeks. All the patients received a hypocaloric diet during the study. At the beginning
and the end of the study, the serum levels of ALT and AST and liver steatosis were measured. Findings. A significant decrease in the
level of ALT enzymes was observed in the control group at the end of the study (𝑃 = 0.004). In the olive oil group, both enzymes
decreased compared to baselinemeasurements (𝑃 < 0.01).There were significant differences in the ALT andAST levels between the
two groups (𝑃 < 0.02).The severity of liver steatosis did not change significantly during the study.Conclusion.The consumption of a
low calorie diet enriched with olive oil, along with slight weight reduction, reinforces the desired effects of weight loss in improving
the levels of the hepatic enzymes.
1. Introduction
At present, nonalcoholic fatty liver disease (NAFLD) is the
most common cause of elevated serum aminotransferase [1].
In fact, elevated serum alanine aminotransferase (ALT) not
only is a consequence of the NAFLD but also predicts the
progression of the disease [2]. Recent findings point out that
NAFLD may be linked to an increased risk of cardiovascular
disease (CVD), which is the most common cause of overall
mortality [3, 4].Many long-term follow-up studies ofNAFLD
found a strong link betweenmortality related to the coronary
artery disease and NAFLD. Another common reason for
mortality in the NAFLD patients is hepatic failure, especially
in those with nonalcoholic steatohepatitis (NASH) [5–7].The
increased levels of the liver enzymes including ALT, aspartate
aminotransferase (AST), and 𝛾-glutamyl transferase (GGT)
are the markers of NAFLD and the occurrence of CVD
events in both nondiabetic subjects and the patients with type
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2 diabetes [8]. Studies have also shown that ALT predicts
cardiovascular events, early carotid atherosclerosis [9, 10].
This suggests that NAFLD is associated with coronary heart
disease (CHD), independent of the other features of the
metabolic syndrome.The studies showed that the prevalence
of NAFLD in Iran was relatively high and the people with
NAFLD had a higher risk of 10-year CVD events than the
individuals without NAFLD [4, 11].
Animal models and human studies suggest that the
dietary factors play a key role in the progression ofNAFLD. In
particular, the amount and type of dietary fat can affect fatty
infiltration and lipid peroxidation in NAFLD [12, 13]. There
is little research on the effects of the type of dietary fat in
NAFLD [14]. Recently, the Mediterranean diet has received
attention as a diet that prevents NAFLD and cardiovascular
disease. It is known that olive oil, which is rich in the
monounsaturated fatty acids (MUFAs), is responsible for the
major part of the beneficial effects of the Mediterranean diet
[15–17].
Animal studies indicated that olive oil consumption leads
to an increase in the release of the triglycerides from the liver
and a decrease in the flux of free fatty acids (FFAs) from
the peripheral adipose tissue back to the liver [18]. In rats, a
diet rich in olive oil led to the remission of hepatic steatosis
[19]. In other animal studies, liver damage was found to be
decreased in rats receiving olive oil, compared to those given
polyunsaturated oil [20]. However, the role of MUFA or olive
oil in human NAFLD is yet to be demonstrated.
Some human studies have been conducted on the effects
of a high-fat diet (40%) on the serum ALT enzyme and the
severity of steatosis in patients with type 2 diabetes [21, 22].
There is only one study on the effects of olive oil in
patients withNAFLDwhowere given a low-fat diet (20% fats)
[23]. In this study no significant changes were found in the
ALT and AST levels.
Considering the high prevalence of NAFLD in Iran, we
have tried to examine the effects of extra virgin olive oil in
a normal fat diet (30%) on the serum levels of the ALT and
AST enzymes and on the severity of steatosis in the NAFLD
patients on a weight-loss diet.
2. Materials and Methods
2.1. e Subjects. This clinical trial was carried out on 50
patients (19 women and 31 men) with nonalcoholic fatty liver
in Tehran, Iran. The mean age was 45.91 ± 9.61 years, and
the mean BMI was 29.7 ± 0.58Kg/m2. The clinical inclusion
criteria were the increase of the AST and ALT enzymes (U/L
< 30 in men and <20 in women), the elimination of all
other causes for the increase in the liver enzymes (other
liver diseases), age of 20–65 years, BMI of 25–40 kg/m2, no
use of hepatotoxic medicines, no history of ≥30 gr/d alcohol
consumption, no CVD, no diabetes, no pregnancy or breast
feeding, no smoking, no consumption of mineral and mul-
tivitamins supplements, no consumption of olive products,
and lipid-lowering medicines in the last three months. All
the subjects gave their informed consent in writing. The trial
was approved by the TUMS Research Ethical Committee
and was registered in the Iranian website for clinical trials
(http://www.irct.ir, code: IRCT201111022709N20).
2.2. Sample Size. The sample size was calculated based on
the only published paper in this area at the time of this
study, which showed that amodifiedMediterranean diet (rich
in olive oil) caused a reduction in the ALT levels in obese
patients with type 2 diabetes [21]. To determine the outcome
with type one (𝛼) and type two errors (𝛽) of 0.05 and 0.20
(power = 80%) and 10% dropouts, 25 subjects in each group
were recruited.
2.3. e Study Design. The study was a randomized, single-
blind trial. The patients were randomly chosen by the qual-
ified experts. The sample was recruited from the visiting
patients in the gastroenterology ward of Imam Khomeini’s
Training and Treatment Hospital in Tehran, Iran. Then, the
necessary briefing and the aims of the study were given to the
subjects, and they were requested not to use olive oil for 10
days before starting the study.Then, the patients were divided
into two groups by using the method of random allocation.
The olive oil group received the hypocaloric diet enriched
with olive oil (20% of total energy intake) while the control
group received the hypocaloric diet with normal fat. None of
the participants know about the other group and alternative
treatment.
2.3.1. Experimental Design for the Weight-Loss Diet. At the
beginning of the study, the weight-loss diet was set with an
objective of 5% weight reduction during three months of
the study. The daily energy intake recommendations were
50% carbohydrates, 20% protein, and 30% fats for both
groups. First, the energy required by each individual was
calculated on the basis of their age, weight, and height and
the gram quantity of eachmacronutrient was estimated based
on the information. Then, the personalized diet was set, and
different food groups and the food-exchanging table were
explained to the subjects.
In this diet, 20% of the total fat (30%) was allocated to
olive oil or the usual culinary fat, for the olive oil group and
the control group, respectively. The remaining 10% of the
required daily amount of fat was provided from the other
nutrition groups such as dairy, meats, and nuts. Necessary
training was given to the patients in the olive oil group
for the correct way of consumption of the olive oil at the
beginning of the study. The patients in both groups were
asked not to change the advised diet and their level of physical
activities.
2.3.2. e Preparation Method for Olive Oil. The virgin olive
oil used in this study belonged to the Eteka brand (Roudbar,
Iran), affiliated to the Khoramshahr Extraction oil company.
The required oil dosage was allocated and supplied to each
patient every week. In order to reduce the bias in the
consumption amount of oil, identical measuring mugs were
given to each patient with the required oil amount printed on
it.
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Table 1: Demographic characteristics of the study subjects.
Variables Groups 𝑃 value
Olive oil (𝑛 = 25) Control (𝑛 = 28)††
Sex
Male 13 (61.9%) 13 (61.9%)
0.993∗∗
Female 8 (38.1%) 9 (40.9%)
Age (Year) 46.14 ± 8.44 45.68 ± 10.8 0.87∗
Disease duration (Year) 7.16 ± 2.4 6.91 ± 2.7 0.72∗
Type of oil 0.83∗∗
Nonhydrogenated oil† 15 (71.4%) 16 (73.76%)
Hydrogenated oil 2 (9.5%) 3 (13.6%)
Both 4 (9.1%) 3 (13/6%)
∗
푃 value reported based on Independent Sample 푡-test; ∗∗푃 value reported based on Chi-Square test. Quantitative data represented as mean ± SD or median
(min-max). Qualitative data reported as frequency (percentage). †In all of the patients using nonhydrogenated oil was sunflower oil. ††Was given usual daily
consuming oil.
2.4. Measurements
2.4.1. Demographic Data. The demographic questionnaires
were completed by interview. The height was measured by
using the stadiometer attached to the scale with an accuracy
of 0.5 cm without shoes; the weight was also measured by
the Seca scale, with an accuracy of 0.5 kg, in the fasting
state, and with minimum clothing without shoes. The waist
circumferencewasmeasured by using the stripmeter, with an
accuracy of 0.5 cm, with minimum clothing in the standing
position at the beginning and the end of the study. The body
mass index (BMI) was calculated using weight in kg divided
by meters squared. All the patients’ medical and drug history
were recorded. The level of physical activities was evaluated
by using the physical activity international questionnaire.
2.4.2. Dietary Intake. The food record questionnaires were
completed over three days (two normal days and one holiday)
at the beginning and at the end of the study to estimate the
consumption of energy, carbohydrates, protein, fat, vitamins
C and E, beta carotene, zinc, selenium, and fiber. The
nutrition information was analyzed with the Nutritionist IV
software.
2.4.3. Biochemical Assessment. From each patient, 10 cc ve-
nous blood sample was taken from the vein in the left arm,
after 12–14-hour fasting. The blood samples were taken with
the patients in the sitting position, in the Laboratory of Imam
Khomeini’s Training and Treatment Center, Tehran, Iran.The
blood serum was immediately separated using the centrifuge
in the 3000th (temperature of 4∘C) cycle. The AST and ALT
hepatic enzymes in the samples were measured immediately
with the enzymatic colorimetric method.
2.4.4. Ultrasound Imaging of the Liver. The severity of the
steatosis was measured with an ultrasound in the afternoon,
eight hours after a light breakfast. The liver ultrasound was
carried out with a 3.5-MHz curvilinear probe by a radiologist.
The patients were classified into three groups based on the
fat accumulation in their livers, that is, slight, moderate, and
severe degrees.
2.5. Statistical Analysis. The Statistical Package for the Social
Sciences software (version 20, SPSS Inc., Chicago, IL, USA)
was used to analyze the data. The Kolmogorov-Smirnov test
was carried out to test the normality of the distribution. All
variables were reported as mean ± standard deviation (SD).
The Chi-Square’s test and the independent 𝑡-test was used
for analysing the variables such as physical activity, the type
of medicines consumed, the type of edible oil used, and the
severity of steatosis between two groups. Within each group,
the comparisons were done by the paired-sample 𝑡-test and
by the McNemar’s test variables. A 𝑃 < 0.05 was considered
statistically significant.
3. Results
3.1. Demographic Data. Out of the 50 NAFLD patients who
participated in this study, 4 patients were eliminated from the
olive oil group and 3 patients were removed from the control
group. A total of 43 patients completed the trial.Themean age
of the subjects was 46.14 ± 8.44 and 45.68 ± 10.8 in the olive
oil group and in the control group, respectively. Moreover,
the mean BMI in the olive oil group was 29.64 ± 3.93 and
in the control group was 29.9 ± 3.77 kg/m2. There were no
significant differences in gender, age, duration of disease
(Table 1), weight, BMI, and waist circumstance (Table 2)
between the two groups at the beginning and the end of the
study. Given the energy limitation imposed at the beginning
of the study, a significant weight reduction of 3.45 kg (4.33%)
was observed in the olive oil group and a weight reduction of
2.89 kg (3.54%) was seen in the control group at the end of the
study (𝑃 < 0/001) (Table 2).
As shown in Table 3, there was a significant decreased
intake in total energy, carbohydrates, proteins, fat, PUFA, and
saturated fatty acids (SFA) in each group and a significant
difference in the poly unsaturated fatty acids (PUFA) and the
monounsaturated fatty acids (MUFA) intake between the two
groups (𝑃 < 0/001).
3.2. AST and ALT Levels and the Severity of Steatosis. There
was no significant difference at the beginning of the study in
the serumAST andALT levels between the two groups. At the
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Table 2: Anthropometric measurements at baseline and the end of study.
Variables Groups 𝑃 value
Olive oil (𝑛 = 25) control (𝑛 = 28)
𝑊 at baseline (cm) 79.65 ± 11 81.65 ± 13.6 0.58∗
𝑊 at end-of-trial (cm) 76.2 ± 10.1 78.7 ± 12.9 0.47∗
𝑃 value <0.001∗∗ <0.001∗∗
BMI at baseline (kg/m2) 29.64 ± 3.93 29.9 ± 3.77
BMI at end-of-trial (kg/m2) 28.4 ± 3.91 29.13 ± 3.8 0.81∗
𝑃 value <0.001∗∗ <0.001∗∗ 0.68∗
WC at baseline (cm) 103.8 ± 10.81 104.18 ± 10.62 0.92∗
WC at end-of-trial (cm) 100.61 ± 10.1 102.13 ± 10.2 0.63∗
𝑃 value <0.001∗∗ <0.001∗∗
∗
푃 value reported based on Independent Sample 푡-test; ∗∗푃 value reported based on Paired 푡-test. Quantitative data represented as mean ± SD or median
(min-max).푊 = weight, BMI = body mass index, and WC = waist circumference.
end of the study, a significant decrease was seen in the ALT
and AST levels in the olive oil group (𝑃 < 0.01), compared to
the control group.Moreover, therewas a significant difference
in both enzymes between the two groups at the end of the
study (𝑃 < 0.05). Although the intragroup liver fat assessment
revealed an improvement in both groups (more in the olive
oil), there was no significant statistical difference in steatosis
between the two groups at the end of the study (Table 4).
4. Discussion
In the present study, there was a significant decrease in weight
and the ALT and AST levels observed at the end of the study,
in both the olive oil group and the control group. Moreover,
decrease in the ALT and AST levels in the olive oil group was
significantly higher than the control group.
Weight reduction is the first treatment line in the patients
suffering from nonalcoholic fatty liver and can motivate the
improvement of steatosis and the aminotransferase levels
[24]. One study has observed that 5% of weight decrease is
enough to decrease the serum’s ALT value and to improve
steatosis, while a minimum of 9% weight loss is necessary
for a significant improvement of NASH [25]. Another study
indicated that the patients with more than 7% of their base
weight reduction experienced significant improvement in
steatosis, inflammation, and the score of NASH tissue activity
compared to the patients whose weight loss is less than 7%
[26]. Moreover, a weight-loss diet with a goal of 8% initial
weight decrease in obese women for a period of 3 to 6months
showed that the effect of weight loss on the improvement of
steatosis depends on the rate of weight loss and the initial
content of liver fat [27]. In our research, none of the patients
had a high or severe steatosis at the beginning of the study and
the weight loss was less than 7% in both groups at the end of
the study.
Dietary components, particularly the type and the
amount of fats, are crucial for liver fat accumulation and are
responsible for 15%of the liver fat content.Thedietary fats can
exert their role in liver steatosis both directly and indirectly
(via its influence on adipose tissues) [28]. The studies carried
out in this field are limited to the survey of the effects of
the modified Mediterranean diet with high fat content and
MUFA and its comparison to a low-fat diet in the patients
with insulin resistance.
Our research is the first study that has surveyed the
effects of the MUFA (from olive oil source) in a diet with
normal fat content (30%) administered to the patients with
nonalcoholic fatty liver. In one study a balanced-fat diet rich
in olive oil rather than sunflower oil after one month leading
to a decrease in steatosis and the hepatic enzymes in rats was
observed. In human, one study reported that a high-fat (45%)
and high-MUFAdiet lead to the decrease of the ALT enzymes
[21]. These findings are in concurrence with our study. In
another study, the patients with NAFLD in the intervention
group received a high-MUFA diet (olive oil or canola) for
six months [23]. The total content of fat in their diet was
20% of the daily energy intake. Contrary to our study, the
daily consumption of 20 g of olive oil had no effect on the
serum aminotransferase. The low-fat diet in this study could
be a reason for the significant decrease in steatosis. However,
the improvement in liver fat content was not adequate for a
significant decrease in the aminotransferases.
In a study in the patients with type 2 diabetes it was
observed that the percentage of liver fat content in theMUFA-
receiving groups with or without exercise had a significant
decrease as compared to the groups receiving carbohydrate
(CHO) with or without exercise [22].
The beneficial effects of the MUFAs on the hepatic fat
content can be explained by the more rapid oxidization of
the MUFAs than the saturated fatty acids in the postprandial
phase. The more favorable MUFAs deposit in the adipose
tissue rather than in the liver following a diet rich in MUFAs
may help avoid fat deposition in the liver [29]. In addition, a
high-MUFA diet stimulates the activity of lipoprotein lipase
more than a diet rich in saturated fats that leads to increase
in clearance of circulating triglyceride-rich lipoproteins [30].
In addition to type, the amount of fat also plays a role in the
pathogenesis and, probably, in the treatment of fatty liver as
well. In our study, the amount of MUFA was less than 20%.
On the other hand, recent studies on nutritional genomics
supported a key role of gene-diet interaction in NAFLD
development [31]. For example, it is suggested that the
obesity-associated (FTO) gene levels in the liver are involved
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Table 3: Dietary intake of study participants, at baseline and after intervention.
Variables Groups Before After 𝑃 value◼
Mean ± SD Mean ± SD
Energy (Kcal/day)
Olive oil 2613.8 ± 662.3 1756.5 ± 538 <0.001
Control 2449.2 ± 723.2 1695 ± 527.1 0.001
𝑃 value∗ 0.44 0.7
Protein (g/day)
Olive oil 79.5 ± 24.28 63.92 ± 23.8 0.001
Control 82.68 ± 23.18 61.5 ± 22.13 0.005
𝑃 value∗ 0.69 0.74
Carbohydrates (g/day)
Olive oil 374.16 ± 79.1 252.5 ± 53.7 0.004
Control 334.1 ± 62.6 246.6 ± 49.3 0.005
𝑃 value∗ 0.22 0.832
FAT (g/day)
Olive oil 92.41 ± 55.38 57.3 ± 23.18 0.001
Control 86.03 ± 36.64 55.33 ± 20.1 <0.001
𝑃 value∗ 0.58 0.59
SFA (g/day)
Olive oil 23.94 ± 9.5 13.67 ± 8.18 0.003
Control 28.93 ± 8.45 14.03 ± 6.09 0.001
𝑃 value∗ 0.411 0.870
MUFA (g/day)
Olive oil 24.95 ± 9.28 29.27 ± 10.76 0.47
Control 23.53 ± 10.81 †13.45 ± 6.56 0.19
𝑃 value∗ 0.873 <0.001
PUFA (g/day)
Olive oil 37.88 ± 14.63 12.43 ± 4.36 0.002
Control 32.52 ± 11.8 †26.3 ± 8.4 0.003
𝑃 value∗ 0.275 <0.001
Fiber (g/day)
Olive oil 12.49 ± 5.8 10.94 ± 6.5 0.333
Control 13.4 ± 5.32 11.69 ± 6.23 0.291
𝑃 value∗ 0.595 0.070
Beta-carotene (𝜇g/d)
Olive oil 245/7 ± 57.28 226.68 ± 30.76 0.234
Control 239.23 ± 95.81 218.82 ± 72.54 0.171
𝑃 value 0.708 0.895
Vitamin E (mg/day)
Olive oil 5.1 ± 3.5 2.53 ± 2.64 0.174
Control 4.31 ± 3.1 2.16 ± 1.79 0.122
𝑃 value∗ 0.634 0.587
Vitamin C (mg/day)
Olive oil 61.25 ± 42.95 70.95 ± 32.95 0.621
Control 63.9 ± 22.72 68.05 ± 32.51 0.404
𝑃 value∗ 0.863 0.761
Selenium (mg/day)
Olive oil 0.09 ± 0.04 0.07 ± 0.04 0.134
Control 0.13 ± 0.17 0.12 ± 0.12 0.823
𝑃 value∗ 0.366 0.277
Zinc (mg/day)
Olive oil 7.04 ± 4.62 10.94 ± 6.5 0.895
Control 8/04 ± 4.9 11.69 ± 6.23 0.767
𝑃 value∗ 0.711 0.615
∗
푃 value reported based on Independent Sample 푡-test; ◼푃 value reported based on Paired 푡-test; SFAs = saturated fatty acids, PUFAs = polyunsaturated fatty
acids, and MUFAs = monounsaturated fatty acids.
in oxidative stress and lipid deposition, which characterize
NAFLD [32]. The level of FTO gene expression is related
to the level of dietary macronutrients [33]. Interestingly, the
FTO genotype can affect the success of lifestyle interventions
in the prevention and treatment of obesity [34].
Moreover, the observed difference may be related to the
method of measuring the fatty contents [35]. The NMR
(Nuclear Magnetic Resonance) or the spectroscopic golden
standard method is used for measuring the existing fat
percentage in the liver. It has high precision and accuracy
and is considered as the strength of the mentioned study,
as described by the researcher. However, in our study,
ultrasonographywas used because of its cost effectiveness and
prevalence. This method has some limitations, including the
fact that the results obtained by it depend on the mastery and
expertise skills of the operator and the detecting sensitivity
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Table 4: Aminotransferase and severity of steatosis at the start and the end of study.
Variables Groups Before After
Mean ± SD Mean ± SD
𝑃 value◼
ALT (IU/dl)
Olive oil 48 ± 12.9 35.71 ± 11.33 <0.001
Control 50.82 ± 10.37 46.18 ± 10.26 0.004
𝑃 value∗ 0.43 0.003
AST (IU/dl)
Olive oil 34.53 ± 5.3 26.1 ± 5.4 <0.001
Control 34.68 ± 8.9 32.28 ± 2.2 0.25
𝑃 value∗ 0.94 0.002
𝑃 value©
Steatosis𝑁(%)
Slight
Olive oil
10 (47.61%) 15 (71.42%)
0.008Moderate 11 (52.38%) 6 (28.57%)
Severe 0 0
Slight
Control
7 (31.81%) 10 (45.46%)
0.17Moderate 15 (68.18%) 12 (54.54%)
Severe 0 0
𝑃 value∗∗ 0.23 0.13
∗
푃 value reported based on Paired Sample 푡-test. ◼푃 value reported based on Independent Sample 푡-test. ©푃 value reported based on McNemar. ∗∗푃 value
reported based on Chi-Square. 푃 < 0.05: significant.
of ultrasonography decreases with a degree of fat infiltration
less than 30% [2]. Considering the low grade of steatosis
in our patients, in contrast to the Nigma study where the
patients had higher liver fat, the use of ultrasonography may
prevent the obtaining of accurate information on the changes
of liver steatosis. Another limitation of this study was sample
size and short follow-up duration. A larger group of patients
and longer follow-up period are needed to confirm the
results.
5. Conclusion
In conclusion, the results of this study suggest that normal fat
percentage (30%) in a diet containing olive oil (consumption
the equivalent of 20% of total calorie intake from virgin
olive oil) along with slight weight loss (approximately 5%)
reinforces the desired effects of weight loss in improving the
levels of the ALT and AST enzymes.
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